Free Trial

Elevation Oncology (ELEV) Competitors

Elevation Oncology logo
$0.32 0.00 (-1.25%)
As of 02:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ELEV vs. SNTI, ZURA, CLLS, CLYM, IZTC, OCX, ADAG, CRVO, TCRX, and IMAB

Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Senti Biosciences (SNTI), Zura Bio (ZURA), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), TScan Therapeutics (TCRX), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry.

Elevation Oncology vs.

Senti Biosciences (NASDAQ:SNTI) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Senti Biosciences had 3 more articles in the media than Elevation Oncology. MarketBeat recorded 4 mentions for Senti Biosciences and 1 mentions for Elevation Oncology. Senti Biosciences' average media sentiment score of 0.00 beat Elevation Oncology's score of -1.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Senti Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elevation Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Elevation Oncology received 34 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 66.10% of users gave Elevation Oncology an outperform vote while only 45.45% of users gave Senti Biosciences an outperform vote.

CompanyUnderperformOutperform
Senti BiosciencesOutperform Votes
5
45.45%
Underperform Votes
6
54.55%
Elevation OncologyOutperform Votes
39
66.10%
Underperform Votes
20
33.90%

Senti Biosciences presently has a consensus price target of $12.00, indicating a potential upside of 293.44%. Elevation Oncology has a consensus price target of $3.39, indicating a potential upside of 954.74%. Given Elevation Oncology's higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Senti Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Elevation Oncology
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

Senti Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

Elevation Oncology has lower revenue, but higher earnings than Senti Biosciences. Elevation Oncology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Senti Biosciences$2.56M31.07-$71.06M-$10.84-0.28
Elevation OncologyN/AN/A-$45.70M-$0.82-0.39

Elevation Oncology's return on equity of -59.73% beat Senti Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Senti BiosciencesN/A -154.84% -77.42%
Elevation Oncology N/A -59.73%-40.05%

Summary

Elevation Oncology beats Senti Biosciences on 10 of the 16 factors compared between the two stocks.

Get Elevation Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELEV vs. The Competition

MetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$19.01M$2.93B$5.33B$8.39B
Dividend YieldN/A1.63%5.21%4.10%
P/E Ratio-0.3931.1826.7719.70
Price / SalesN/A398.78393.27122.35
Price / CashN/A168.6838.2534.62
Price / Book0.253.236.774.50
Net Income-$45.70M-$72.35M$3.23B$248.22M
7 Day Performance13.63%2.49%0.43%-0.80%
1 Month Performance-15.26%2.45%9.07%11.52%
1 Year Performance-91.30%-24.98%18.57%8.99%

Elevation Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELEV
Elevation Oncology
2.9037 of 5 stars
$0.32
-1.2%
$3.39
+968.0%
-91.6%$18.77MN/A-0.3940Negative News
SNTI
Senti Biosciences
1.6829 of 5 stars
$3.26
flat
$12.00
+268.1%
-16.3%$85.02M$2.56M-0.214Gap Up
ZURA
Zura Bio
2.7049 of 5 stars
$1.24
+2.5%
$14.33
+1,055.9%
-81.2%$84.79MN/A-2.343News Coverage
Analyst Revision
Gap Up
CLLS
Cellectis
2.7815 of 5 stars
$1.51
-4.4%
$7.00
+363.6%
-46.2%$83.93M$41.51M-1.16290News Coverage
Analyst Downgrade
CLYM
Climb Bio
2.6993 of 5 stars
$1.24
+4.2%
$10.00
+706.5%
N/A$83.79MN/A-0.589News Coverage
Positive News
Analyst Upgrade
Gap Up
IZTC
Invizyne Technologies
N/A$13.01
+4.0%
N/AN/A$81.34MN/A0.00N/A
OCX
OncoCyte
2.6327 of 5 stars
$2.81
-2.1%
$4.42
+57.2%
+18.2%$80.36M$1.88M-0.64120Analyst Forecast
ADAG
Adagene
1.7916 of 5 stars
$1.70
+6.2%
$8.00
+370.9%
-37.7%$80.04M$103,204.000.00260News Coverage
Positive News
Gap Up
CRVO
CervoMed
3.3207 of 5 stars
$9.10
+7.2%
$27.50
+202.2%
-55.7%$79.20M$7.14M-4.484
TCRX
TScan Therapeutics
3.9691 of 5 stars
$1.37
+7.9%
$8.50
+520.4%
-84.9%$77.53M$4.42M-1.29100Insider Trade
Gap Up
IMAB
I-Mab
3.0326 of 5 stars
$0.95
+7.4%
$5.50
+482.0%
-40.3%$77.02M$3.27M0.00380

Related Companies and Tools


This page (NASDAQ:ELEV) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners